Flumadine

Flumadine (rimantadine) is a medical and veterinary antiviral agent, a derivative of amantadine and nucleosides similar in structure, the least toxic among known similar compounds, active against strains of influenza A virus, including very virulent H5N1 strains, which are characterized by high patient mortality. At a therapeutic concentration, it blocks the binding of viral particles to the surface of hepatocytes. As a result of this action, the drug sharply reduces the replication of these viruses. Orally suppresses the early stage of specific reproduction of the influenza virus: after introduction into the body, it penetrates from the mucous membrane of the upper respiratory tract into the blood. The properties of the shells do not change (this is not typical for all representatives of dopamine-betahydroxylic acids). Rimantadine is subsequently resorbed in monocytes. Some strains of the influenza virus are resistant to this drug (not always). Poorly absorbed when taken orally. Pharmacokinetics: intramuscular injection accumulates rapidly, reaching equilibrium concentration by the third or fourth day. The half-life of rimantadine is 14-26 hours and increases to 41 hours during repeated dosing several days apart. The maximum concentration of rimantadine in plasma is maintained 75-85 and 92 hours after the first and second injection. Rimantadine is metabolized to form hydroxylated products; excreted both in urine and bile. Plasma clearance decreases in patients with nonfunctional polycytes or GGT deficiency (hepatocellular granulation) after initiation of use and approaches zero by 96 hours after the first use. The highest concentration of flumadine (more than 50%) in the body is found in red blood cells; it is also found in the liver with much smaller amounts than in the blood. In newborns and infants, high concentrations of rimantadine are found in breast milk, so increased doses are required when used in patients in this group. It is also possible for use with body fluids in cats or dogs due to their ability to transport rimantadine from the yellow powder and melanin of the eyes, conjunctiva and respiratory mucosa at a higher rate. Cigarette smokers are also a high-risk group for rimantadine-induced infections. Medical use is contraindicated in people with hypersensitivity to the active substance or other azidine compounds, or with impaired thyroid or liver function. Pregnancy carries a risk of hepatotoxicity, sometimes leading to death. The effect of flumandin in infants requires consultation with The use of rimantadine in people with GGT deficiency is associated with a weakening of rimantadine properties, an increase in dose when the therapeutic approach is ineffective; influence on psychomotor data and convulsive phenomena, some blood tests are specific to this given